AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03648463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection
Description: Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
Study NCT03648463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection
Description: Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
Study NCT01784003 — intervention group
Intervention type: DEVICE
Intervention: Powered ankle-foot prosthesis
Study NCT02644252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Carboplatin AUC=5
Study NCT05022043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Presepsin
Description: Estimation of Serum Presepsin at time of admission
Study NCT00565019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: * Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~* Doses will range from 60-120 mg depending on extent of the disease.~* Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~* PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: >10 cm2, dosage 100-120 mg
Study NCT01999712 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
Study NCT02720250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 chicken eggs
Description: Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
Study NCT02720250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular chicken eggs
Description: Intake of 3 regular chicken eggs per day for three weeks.
Study NCT02019017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 25 IU
Study NCT02019017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 50 IU
Study NCT00639496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine
Description: 600 mg x 3, for 12 months
Study NCT00639496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT00539318 — intervention group
Intervention type: PROCEDURE
Intervention: Blood drawing
Description: Once when enroll in study
Study NCT04366713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Administered orally once daily as a single daily dose of 240 mg
Study NCT04366713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
Study NCT04366713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally for prophylaxis for 28 days and then as needed
Study NCT00788918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Description: Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
Study NCT00846469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CCTA (coronary computed tomography angiography)
Description: A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
Study NCT00846469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control section
Description: Normal emergency room treatment for symptoms of chest pain.
Study NCT02639923 — intervention group
Intervention type: PROCEDURE
Intervention: Drawing of 7ml peripheral blood
Description: puncture peripheral vein
Study NCT03304262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
Study NCT03304262 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
Study NCT02137304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
Description: Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
Study NCT02232724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choline PET/CT and Dual time point FDG PET/CT
Description: Choline PET/CT and dual time point FDG PET/CT
Study NCT00441480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols esters
Description: 1.6g phytosterols and 1.3g omega-3 fatty acids per day
Study NCT00441480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 gr of corn oil
Study NCT02644252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Vinorelbine 30 mg/m2
Study NCT02273414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS - rising dose
Study NCT02273414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00663338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
Study NCT00418301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulation and PET Scan
Description: Imaging procedure to assess spinal Cord Stimulation.
Study NCT02644252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 8: Capsule vinorelbine 60 mg/m2
Study NCT02644252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol 300 mg x 3 daily until progression
Study NCT02644252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1 capsule x 3 daily until progression
Study NCT05841927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplement
Description: Docosahexaenoic acid supplement
Study NCT05841927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ASD placebo
Description: ASD placebo
Study NCT05918731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Management
Description: A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file.
Study NCT02384135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off
Study NCT03321838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: accommodative/vergence therapy
Description: Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
Study NCT03354767 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic and aortic valve surgery
Study NCT02944708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chemotherapy
Study NCT02944708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Study NCT02944708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy 1
Study NCT02944708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy 2
Study NCT03367403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV
Study NCT03367403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT03367403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: Administered orally
Study NCT00194077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
Study NCT00194077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects in phase 2 will be randomized to active abilify or placebo
Study NCT03444103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clazakizumab / Clazakizumab
Description: Humanized monoclonal anti-IL-6 antibody
Study NCT03444103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Clazakizumab
Description: 0.9% Saline
Study NCT00272831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 mg twice daily
Study NCT00272831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice daily
Study NCT02008942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 Aspirin Capsules
Description: 325 mg aspirin; once per day for 10 days
Study NCT02008942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated aspirin caplets
Description: 325 mg aspirin; once per day for 10 days
Study NCT03633994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
Study NCT03633994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline bladder instillation
Study NCT01005199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
Study NCT01005199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib 2 x 400 mg daily
Study NCT01335191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subcutaneous injections of Placebo at Day 0 and Week 3.
Study NCT00822783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Study NCT00822783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00920283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono Carbostent Carbofilm™ Coated Coronary Stent
Study NCT00920283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Driver Cobalt Alloy Coronary Stent
Study NCT00971594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: 1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk
Study NCT00971594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AEX
Description: Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
Study NCT02646072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine ophthalmic solution 0.45%
Description: Indicated for the treatment of pain and inflammation following cataract surgery.
Study NCT01452724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT01452724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
Study NCT01452724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
Study NCT01452724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
Study NCT03607071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone and taper
Description: Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
Study NCT02281968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
Study NCT02281968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03685110 — intervention group
Intervention type: DEVICE
Intervention: CoreHip Total Hip Arthroplasty
Description: Replacement of the Hip Joint
Study NCT05467488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photofunctionalization
Description: UVA and UVC photofunctionalization of dental implants
Study NCT01498588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
Study NCT01498588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
Study NCT01498588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
Study NCT06790615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl prednisolone acetate
Description: methyl prednisolone acetate was injected after the aspiration
Study NCT06790615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silk suture
Description: The silk suture was used for threading technique
Study NCT01498588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
Study NCT06792383 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: quality of life
Description: The following assessment tools will be proposed to patients:~* Quality of Life in Epilepsy (QOLIE-31)26~* Dissociative Experience Scale (DES)27~* Symptom Checklist-90 (SCL-90)28~* Irritability Questionnaire (I-EPI)29~* Beck Depression Inventory II (BDI-II)30~* State-Trait Anxiety Inventory Y-1 e Y-2 (STAI)31~* Epilepsy Stigma Scale modificata32 These assessment tools are validated and used universally, and will allow the collection of information on the psychological and psychiatric functioning of the patients.
Study NCT02919410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iodophor-impregnated adhesive drapes
Study NCT02919410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No adhesive drapes
Study NCT06791746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound Staphylococcal lysostaphin mouthrinse
Description: Lysostaphin is a proteolytic enzyme produced by a specific species of Staphylococcus, uniquely capable of cleaving the cross-linking pentaglycine bridges within the cell walls of Staphylococcus aureus.
Study NCT06791746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine mouthrinse
Description: Chlorhexidine mouthrinse offers a cost-effective prophylactic approach to preventing OM.
Study NCT03168841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinaconazole Topical
Description: Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
Study NCT04238689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB31F
Description: Monoclonal antibody
Study NCT01437267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine
Study NCT01437267 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine
Study NCT01437267 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide (PS) vaccine
Study NCT02434653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring hemoglobin levels following anemia associated symptoms
Description: Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
Study NCT02434653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia
Description: Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
Study NCT03364491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
Study NCT03364491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
Study NCT03770780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 in combination with Ketamine
Study NCT03770780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combination with Ketamine
Study NCT02140606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cafusertib Hydrochloride
Description: Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
Study NCT03415581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxycodone
Description: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
Study NCT03415581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxycodone
Description: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
Study NCT03415581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue Session
Description: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
Study NCT03415581 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Session
Description: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
Study NCT01696799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Econazole Nitrate
Study NCT01696799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate
Study NCT01696799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02350075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implants installation
Description: Dental implants installation is a procedure to insert dental implants into alveolar bone.